Recent US IPO activity remains elevated, with 249 deals priced year-to-date through late September 2026 and several large offerings slated for the final days of the month, including Oura Inc. and Accelevation Holdings Corp. on September 30. Equity market strength, AI-related investor demand, and a constructive backdrop for biotechs have supported issuance, though recent postponements highlight valuation mismatches and selectivity. The Renaissance IPO Index has outperformed broader benchmarks amid contained volatility, while upcoming catalysts include additional filings and potential pricings into October and November. Trader sentiment reflects the open window and pipeline momentum heading into year-end.